Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 12Ovarian Neoplasms 3Gestational Trophoblastic Disease 2Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Melanoma 1Liver Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cervical Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Advanced Cervical Cancer 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ovarian Neoplasms × toripalimab × Gynecologic × Clear all
NCT04918186 2026-05-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting
60 enrolled
Gynecologic

Ovarian Neoplasms

NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05342506 2022-04-22

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Peking Union Medical College Hospital

Phase 2 Unknown
30 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡